Pharmacotherapies for lipid modification: Beyond the statins

Nature Reviews Cardiology

Volumn 10, Issue 10, 2013, Pages 560-570

  Gotto, Antonio M ^a   Moon, Jennifer E ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; DALCETRAPIB; ETC 1002; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FATTY ACID SYNTHASE INHIBITOR; FENOFIBRATE; FENOFIBRATE PLUS SIMVASTATIN; FENOFIBRIC ACID; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LAROPIPRANT PLUS NICOTINIC ACID; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MIPOMERSEN; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ACUTE CORONARY SYNDROME; AMINOTRANSFERASE BLOOD LEVEL; AORTA STENOSIS; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FAT CONTENT; FATTY LIVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART PROTECTION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INJECTION SITE REACTION; LIPID ABSORPTION; LIPID ANALYSIS; LIPID METABOLISM; LOW DRUG DOSE; METABOLIC ALKALOSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERITONEAL DIALYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; LIPIDS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84884591325     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.117     Document Type: Review

References (114)

1. Baigent, C. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670-1681 (2010).
2. Mihaylova, B. et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380, 581-590 (2012).
3. Taylor, F. et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2013, Issue 1. Art. No.: CD004816. http://dx.doi.org/10.1002/14651858.CD004816.pub5.
4. Kostis, W. J., Cheng, J. Q., Dobrzynski, J. M., Cabrera, J. & Kostis, J. B. Meta-analysis of statin effects in women versus men. J. Am. Coll. Cardiol. 59, 572-582 (2012).
5. Hovingh, G. K., Davidson, M. H., Kastelein, J. J. & O'Connor, A. M. Diagnosis and treatment of familial hypercholesterolemia. Eur. Heart J. 34, 962-971 (2013).
6. Fernandez, G., Spatz, E. S., Jablecki, C. & Phillips, P. S. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve. Clin. J. Med. 78, 393-403 (2011).
7. Hsia, J., MacFadyen, J. G., Monyak, J. & Ridker, P. M. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J. Am. Coll. Cardiol. 57, 1666-1675 (2011).
8. Grundy, S. M. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110, 227-239 (2004). (Pubitemid 38924592)
9. Lambert, G., Sjouke, B., Choque, B., Kastelein, J. J. & Hovingh, G. K. The PCSK9 decade. J. Lipid Res. 53, 2515-2524 (2012).
10. Pinkosky, S. L. et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J. Lipid Res. 54, 134-151 (2013).
11. Ballantyne, C. M., et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in subjects with hypercholesterolemia: the results of a double-blind, parallel group, multicenter, placebo controlled trial. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2013.05.050.
12. Out, C., Groen, A. K. & Brufau, G. Bile acid sequestrants: more than simple resins. Curr. Opin. Lipidol. 23, 43-55 (2012).
13. Hou, R. & Goldberg, A. C. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol. Metab. Clin. North Am. 38, 79-97 (2009).
14. Product information. Colestid®(micronized colestipol hydrochloride tablets; Pharmacia & Upjohn Company, Kalamazoo, MI, USA) [online], http://labeling.pfizer.com/ShowLabeling.aspx?id=593 (2006).
15. Product information. Welchol® (colesevelam hydrochloride; Daiichi Sankyo, Inc., Parsippany, NJ, USA) [online], http://dsi.com/prescribing- information-portlet/getDocument?product=WC&inline=true (2013).
16. Ooi, C. P. & Loke, S. C. Colesevelam for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews, Issue 12. Art. No.: CD009361. http://dx.doi.org/10.1002/14651858.CD009361.pub2.
17. The Lipid Research Clinics Coronary Primary Prevention Trial. Results 1: reduction in incidence of coronary heart disease. JAMA 251, 351-364 (1984).
18. Hujigen, R. et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin. Ther. 32, 615-625 (2010).
19. Kawashiri, M. et al. Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia. Am. J. Cardiol. 109, 364-369 (2012).
20. Wang, L. J. & Song, B. L. Niemann-Pick C1-Like 1 and cholesterol uptake. Biochim. Biophys. Acta 1821, 964-972 (2012).
21. Dembowski, E. & Davidson, M. H. Statin and ezetimibe combination therapy in cardiovascular disease. Curr. Opin. Endocrinol. Diabetes Obes. 16, 183-188 (2009).
22. Product information. Zetia® (ezetimibe; MSD International Gmbh, Lucerne, Switzerland) [online], http://www.merck.com/product/usa/pi-circulars/z/ zetia/zetia-pi.pdf (2013).
23. Product information. Vytorin® (ezetimibe/simvastatin; MSD International Gmbh, Lucerne, Switzerland) [online], http://www.merck.com/ product/usa/pi-circulars/v/vytorin/vytorin-pi.pdf (2013).
24. Product information. Liptruzet® (ezetimibe/atorvastatin; Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA) [online], http://www.merck.com/ product/usa/pi-circulars/l/liptruzet/liptruzet-pi.pdf (2013).
25. Pandor, A. et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J. Intern. Med. 265, 568-580 (2009).
26. Mikhailidis, D. P. et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolemia: systematic review and meta-analysis. Curr. Med. Res. Opin. 27, 1191-1210 (2011).
27. Kastelein, J. J. et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431-1443 (2008). (Pubitemid 351482735)
28. Taylor, A. J. et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 361, 2113-2122 (2008).
29. Fleg, J. L. et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J. Am. Coll. Cardiol. 52, 2198-2205 (2008).
30. Meaney, A. et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J. Clin. Pharmacol. 49, 838-847 (2009).
31. Rossebø, A. B. et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359, 1343-1356 (2008).
32. Baigent, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet 377, 2181-2192 (2011).
33. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00202878 (2012).
34. Hussain, M. M. et al. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J. Lipid Res. 44, 22-32 (2003). (Pubitemid 36114766)
35. Wetterau, J. R. et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 258, 999-1001 (1992).
36. Cuchel, M. et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356, 148-156 (2007). (Pubitemid 46089675)
37. Samaha, F. F., McKenney, J., Bloedon, L. T., Sasiela, W. J. & Rader, D. J. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 5, 497-505 (2008).
38. Cuchel, M. et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, phase 3 study. Lancet 381, 40-46 (2013).
39. Product information. Juxtapid® (lomitapide; Aegerion Pharmaceuticals, Inc., Cambridge, MA, USA) [online], http://www.juxtapid.com/-pdf/Prescribing- Information.pdf (2012).
40. Toth, P. P. Antisense therapy and emerging applications for the management of dyslipidemia. J. Clin. Lipidol. 5, 441-449 (2011).
41. Visser, M. E., Witztum, J. L., Stroes, E. S. & Kastelein, J. J. Antisense oligonucleotides for the treatment of dyslipidemia. Eur. Heart J. 33, 1451-1458 (2012).
42. Product information. Kynamro® (mipomersen sodium; Genzyme Corporation, Cambridge, MA, USA) [online], http://www.kynamro.com/~/media/ Kynamro/Files/KYNAMRO-PI.pdf (2013).
43. Raal, F. J. et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Lancet 375, 998-1006 (2010).
44. Stein, E. A. et al. Apolipoprotein synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126, 2283-2292 (2012).
45. McGowan, M. P. et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE 7, e49006 (2012).
46. FDA Briefing Document. NDA 203568. Mipomersen sodium injection 200 mg/ml. Endocrinologic and Metabolic Drugs Advisory Committee meeting, October 18 2012 [online], http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM323927.pdf (2012).
47. Wilson, P. W., Abbott, R. D. & Castelli, W. P. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 8, 737-741 (1988). (Pubitemid 19005358)
48. Canner, P. L. et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8, 1245-1255 (1986). (Pubitemid 17208898)
49. Frick, M. H. et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, 1237-1245 (1987). (Pubitemid 17147964)
50. Rubins, H. B. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341, 410-418 (1999). (Pubitemid 29362514)
51. Boden, W. E. et al. Niacin in patients with low HDL-cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255-2267 (2011).
52. Armitage, J. M. HPS2-THRIVE: Randomized comparison of extended-release (ER) niacin/laropiprant 2 g daily versus placebo in 25,673 patients at high risk of occlusive vascular events. Presented at ACC Scientific Sessions 2013.
53. Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 366, 1849-1861 (2005).
54. Ginsberg, H. N. et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2010).
55. Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007). (Pubitemid 350146106)
56. Schwartz, G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089-2099 (2012).
57. Voight, B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 380, 572-580 (2012).
58. Barter, P. et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357, 1301-1310 (2007). (Pubitemid 47481452)
59. Ridker, P. M. et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 376, 333-339 (2010).
60. Otocka-Kmiecik, A. et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog. Lipid Res. 51, 314-324 (2012).
61. Khera, A. V. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127-135 (2011).
62. Chapman, M. J. et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 32, 1345-1361 (2011).
63. Miller, M. et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123, 2292-2333 (2011).
64. Digby, J. E., Ruparelia, N. & Choudhury, R. P. Niacin in cardiovascular disease: recent preclinical and clinical developments. Arterioscler. Thromb. Vasc. Biol. 32, 582-588 (2012).
65. Lauring, B. et al. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci. Transl. Med. 4, 148ra115 (2012).
66. MacKay, D., Hathcock, J. & Guarneri, E. Niacin: chemical forms, bioavailability, and health effects. Nutr. Rev. 70, 357-366 (2012).
67. Product information. Niaspan® (niacin extended-release; Abbvie Respiratory LLC, North Chicago, IL, USA) [online], http://www.rxabbvie.com/pdf/ niaspan.pdf (2013).
68. Brinton, E. A. et al. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis. Am. J. Cardiovasc. Drugs 11, 179-187 (2011).
69. Kamanna, V. S., Ganji, S. H. & Kashyap, M. L. The mechanism and mitigation of niacin-induced flushing. Int. J. Clin. Pract. 63, 1369-1377 (2009).
70. Maccubbin, D. L. et al. Effectiveness and safety of laropiprant on niacin-induced flushing. Am. J. Cardiol. 110, 817-822 (2012).
71. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 34, 1279-1291 (2013).
72. Brown, B. G., Canner, P. L., McGovern, M., Guyton, J. R. & Carlson, L. A. In Clinical Lipidology: A Companion to Braunwald's Heart Disease (ed. Ballantyne, C. M.) 298-314 (Elsevier, 2008).
73. Bruckert, E., Labreuche, J. & Amarenco, P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210, 353-361 (2010).
74. Shah, A., Rader, D. J. & Millar, J. S. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 210, 35-40 (2010).
75. Product information. TriCor® (fenofibrate; Abbott Laboratories, Abbott Park, IL, USA) [online], http://www.rxabbvie.com/pdf/tricorpi.pdf (2013).
76. Product information. Lopid® (gemfibrozil; Warner-Lambert Company, New York, NY, USA) [online], http://www.pfizer.com/files/products/uspi-lopid.pdf (2010).
77. Product information. Trilipix® (fenofibric acid; Fournier Industrie Et Sante' Corporation, Dijon, France) [online], http://www.rxabbvie.com/pdf/ trilipix-pi.pdf (2012).
78. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 357, 905-910 (2001).
79. Scott, R. et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32, 493-498 (2009).
80. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102, 21-27 (2000).
81. Manninen, V. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85, 37-45 (1992).
82. Jun, M. et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375, 1875-1884 (2010).
83. Barter, P. J. et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23, 160-167 (2003). (Pubitemid 36231923)
84. Inazu, A. et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323, 1234-1238 (1990). (Pubitemid 20366528)
85. Inazu, A. et al. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J. Clin. Invest. 94, 1872-1882 (1994). (Pubitemid 24348224)
86. Thompson, A. et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 299, 2777-2788 (2008). (Pubitemid 351846853)
87. Ridker, P. M. et al. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18,245 initially healthy women from the Women's Genome Health Study. Circ. Cardiovasc. Genet. 2, 26-33 (2009).
88. Johannsen, T. H., Frikke-Schmidt, R., Schou, J., Nordestgaard, B. G. & Tybjærg-Hansen, A. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J. Am. Coll. Cardiol. 60, 2041-2048 (2012).
89. Zhong, S. et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J. Clin. Invest. 97, 2917-2923 (1996). (Pubitemid 26197108)
90. Agerholm-Larsen, B., Nordestgaard, B. G., Steffensen, R., Jensen, G. & Tybjaerg-Hansen, A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 101, 1907-1912 (2000). (Pubitemid 30225270)
91. Vasan, R. S. et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 120, 2414-2420 (2009).
92. Fayad, Z. A. et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised trial. Lancet 378, 1547-1559 (2011).
93. Lüscher, T. F. et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur. Heart J. 33, 857-865 (2012).
94. Ranalletta, M. et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J. Lipid Res. 51, 2739-2752 (2010).
95. Niesor, E. J. et al. Modulating cholesteryl ester transfer protein activity maintains efficient preß-HDL formation and increases reverse cholesterol transport. J. Lipid Res. 51, 3443-3454 (2010).
96. Niesor, E. J. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Curr. Opin. Lipidol. 22, 288-295 (2011).
97. Gutstein, D. E. et al. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin. Pharmacol. Ther. 91, 109-122 (2012).
98. Yvan-Charvet, L. et al. Cholesterol efflux potential and anti-inflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler. Thromb. Vasc. Biol. 30, 1430-1438 (2010).
99. Castro-Perez, J. et al. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. J. Lipid Res. 52, 1965-1973 (2011).
100. Cannon, C. P. et al. Safety of anacetrapib in patient with or at high risk for coronary heart disease. N. Engl. J. Med. 363, 2406-2415 (2010).
101. Davidson, M. et al. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J. Lipid Res. 54, 467-472 (2013).
102. Gotto, A. M. Jr et al. Effects on lipids and safety following cessation of treatment with cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease [abstract 15035]. Circulation 124, A15035 (2011).
103. Cao, G. et al. Evacetrapib is a novel, potent and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J. Lipid Res. 52, 2169-2176 (2011).
104. Nicholls, S. J. et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 306, 2099-2109 (2011).
105. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01252953 (2013).
106. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01687998 (2013).
107. Shaw, J. A. et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ. Res. 103, 1084-1091 (2008).
108. Waksman, R. et al. A firstinman, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J. Am. Coll. Cardiol. 55, 2727-2735 (2010).
109. Nicholls, S. J. et al. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J. Am. Coll. Cardiol. 47, 992-997 (2006).
110. Hovingh, G. K., Bochem, A. E. & Kastelein, J. J. Apolipoprotein A-I mimetic peptides. Curr. Opin. Lipidol. 21, 481-486 (2010).
111. Davidson, M. H. Apolipoprotein A-I therapy promise, challenges, and disappointment. J. Am. Coll. Cardiol. 57, 1120-1121 (2011).
112. Bailey, D. et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J. Am. Coll. Cardiol. 55, 2580-2589 (2010).
113. Nicholls, S. J. et al. Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J. Am. Coll. Cardiol. 57, 1111-1119 (2011).
114. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).